Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States
Elizabeth M La, Jonathan Graham, David Singer, Daniel Molnar, Sara Poston, Desmond Curran, Jessica Pickett, Frederik Verelst · 2024
Read Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States by Elizabeth M La, Jonathan Graham, David Singer, Daniel Molnar, Sara Poston, Desmond Curran, Jessica Pickett, Frederik Verelst (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11633215.txt.
Description
Elizabeth La and co-authors weigh the costs and gains of a vaccine against a common lung virus for older adults in this 2024 paper. The virus, RSV, causes serious illness in many adults over sixty. The team used a simulation model set in the United States.
The model followed groups month by month over five years, using trial data on how well the vaccine works. Vaccinating about fifty-two million older adults once would prevent a large loss of healthy life years. The added cost came to about four and a half billion dollars from a broad social view. That works out to a cost per healthy year gained that the authors judge good value. Checks with changed inputs mostly kept the verdict, which they present as support for wider use.
Catalog record
| CREATOR | Elizabeth M La, Jonathan Graham, David Singer, Daniel Molnar, Sara Poston, Desmond Curran, Jessica Pickett, Frederik Verelst |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |